Recent Articles from GlobeNewswire

WILMINGTON, DELAWARE, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC) (“Dot Ai” or the “Company”), today announced the appointment of Avi Cohen to its Board of Directors. Cohen brings extensive experience leading technology companies through acquisitions, integration and expansion as Dot Ai enters its next phase of growth following the recent $65 million acquisition of its wholly owned subsidiary, Envoy Technologies.

ROCKVILLE, MD, Oct. 26, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. 

Third Quarter Highlights

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Serapha Bio, Inc. (Serapha), a clinical-stage genetic medicines company committed to transforming the treatment of alpha-1 antitrypsin deficiency (AATD), today announced early clinical data for YOLT-202 (SERP-01), an investigational one-time in vivo base editing therapy, from the ongoing investigator-initiated trial (IIT) evaluating its safety and efficacy in four participants with the PiZZ genotype. Simon Krooss, M.D., Ph.D. of Hannover Medical School presented the data at the European Respiratory Society Alpha-1 Antitrypsin Conference 2026, held on October 23-24 in Barcelona, Spain. The IIT is being conducted through a collaboration between Renji Hospital in Shanghai, China and Hannover Medical School in Germany.

RICHMOND, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO) (the “Company”), a Fortune 1000 company and one of the largest convenience store operators and wholesalers of fuel in the United States, today announced that the Company will host a conference call on Thursday, November 5, 2026 at 9:00 a.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026.

NEWTON, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.

Transformation Efforts Continue to Drive Growth and Profitability 

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

Aoxiangyu 819, Aoyu 966, and Aoyu 288 delivered yield gains of 6.0% to 8.6% over control varieties in two-year national regional trials; 30-day public notice period runs through November 22, 2026

Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated patients

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.

50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- VETmAb Biosciences (VETmAb BIO), a clinical-stage biopharmaceutical company developing transformative biologics for pets, today announced positive clinical proof-of-concept results for VMB-C001a. VMB-C001a is a long-acting anti-IL-23 monoclonal antibody for canine chronic inflammatory enteropathy (CIE), often referred to as inflammatory bowel disease (IBD). VMB-C001a has been granted eligibility for the FDA-CVM’s expanded conditional approval (XCA) pathway.

MONTREAL, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (“Gildan” or the “Company”) today announced it has completed the previously announced sale of HanesBrands Australia (“HAA”) to BBFIT Investments Pte Ltd, an associated entity of BB Retail Capital, a global private investment firm, for approximately $700 million Australian dollars (approximately $490 million US dollars), paid in cash at closing. HAA has been classified as held for sale and reported as discontinued operations in Gildan’s financial statements since the fourth quarter of 2025. Gildan intends to use the net proceeds from the transaction to repay outstanding debt.

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Centauri Minerals Inc. (TSX-V: CENT; OTCQX: CNTIF), a mineral exploration company, has qualified to trade on the OTCQX® Best Market. Centauri Minerals Inc. upgraded to OTCQX from the Pink Limited™ Market.

FORT WORTH, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it plans to release its 2026 third quarter financial and operating results after the close of trading on Monday, November 9, 2026.

Digit humanoid robots to expand to additional GXO sites in 2027, building on industry-first Robots-as-a-Service agreement

RICHMOND, Va., Oct. 26, 2026 (GLOBE NEWSWIRE) -- ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors by gallons in North America, today announced that the Company will host a conference call on Wednesday, November 4, 2026 at 5:00 p.m. Eastern Time to discuss its financial results for the third quarter ended September 30, 2026.

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A

MADRID and BOSTON, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BPGbio, Inc., a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics for patients, today announced encouraging updated results from its Phase 2 clinical trial evaluating BPM31510, an investigational mitochondrial modulator, in combination with standard-of-care radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed glioblastoma multiforme (GBM) patients. The findings were presented on October 24th at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.

Proceeds intended to support the proposed acquisition and planned conversion of a computing center in Youngstown, Ohio

NASA and USGS will compare EarthDaily Constellation data with Landsat observations and evaluate its potential to support AI-ready products and future hybrid government-commercial mission architectures

BEIJING, Oct. 26, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced its third quarter 2026 results and business highlights for the nine-months ended September 30, 2026.

New facility expands industrial seal repair, service, and training capacity following investments in Peru and China.

BERKELEY HEIGHTS, N.J. and WESTFIELD, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Corxel Pharmaceuticals, Inc. (“Corxel US”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for obesity and related cardiometabolic conditions, and Amanat Acquisition Corp (Nasdaq: AMAN) (“Amanat”), a publicly traded special purpose acquisition company, today announced they have entered into a definitive business combination agreement.

SAN FRANCISCO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former Liberty Broadband Corporation (“Liberty Broadband”) investors who received shares of Charter Communications, Inc. (“Charter” or the “Company”) in connection with Charter’s acquisition of Liberty Broadband on August 20, 2026 (“Merger”).

MILLBRAE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of updated data for EIK1001 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain.

SAN FRANCISCO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP, Girard Sharp LLP, and The Hall Firm, Ltd., all national law firms specializing in complex class actions and shareholder rights, announce they have filed a class action lawsuit for violations of the federal securities laws against Compass, Inc. (“Compass” or “Company”) (NYSE: COMP) and certain officers and directors of Compass and Anywhere Real Estate Inc. (“Anywhere”). The class action asserts claims under Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of former Anywhere shareholders who acquired newly issued Compass common stock in direct exchange for their Anywhere securities in the January 9, 2026 stock-for-stock transaction (the “Merger”) by which Compass merged with and acquired Anywhere (the “Class”). The case is pending in the United States District Court for the Southern District of New York and is captioned: Magloire v. Compass, Inc., et al., No. 1:26-cv-08885 (S.D.N.Y.).

Aviatrix Makes Clearance Free to Every Enterprise Through May 1, 2027, So Security Teams Have Time to Patch with a Containment Backstop in Place

MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator’s choice of chemotherapy in chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer who have progressed on endocrine therapy. At this interim analysis for the secondary endpoint of overall survival (“OS”), data were not mature.

SINGAPORE, Oct. 26, 2026 (GLOBE NEWSWIRE) -- EngageLab, an AI-first customer engagement platform, today announced its partnership with CoinW, one of the world's leading cryptocurrency trading platforms. Founded in 2017, CoinW provides a one-stop, intelligent trading experience for users worldwide. CoinW is integrating EngageLab’s AppPush, OTP, and Email capabilities into its transaction messaging infrastructure to support secure and reliable communications for its global user base.

— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — 

FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration’s (FDA’s) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain issues raised by a filer of an abbreviated new drug application (ANDA) referencing VOQUEZNA® (vonoprazan) tablets, BDR Pharmaceuticals, International Pvt. Ltd. (BDR), in litigation brought against the FDA following FDA’s rejection of the ANDA. The litigation was brought to challenge FDA’s June 6, 2025 decision granting Phathom’s Citizen Petition, which agreed with Phathom that VOQUEZNA benefits from 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032. The deadline for comments submitted to the public docket is November 23, 2026.

Former CEO of BNY’s European Bank brings decades of experience across financial services, regulation and strategic transformation

STMicroelectronics introduces first automotive safety combination sensors for mass-market applications

Hydro is pleased to invite investors, analysts, financial media and other stakeholders to its Investor Day on November 25, 2026.

The Singapore-registered EBC Group Foundation, funded entirely by EBC Financial Group, sets one condition for every project it supports and aims to help at least 6,000 people by the end of 2027

Harbin Institute of Technology (HIT)

AXIS-Bench pilot study examines whether AI-generated user interfaces meet interactive accessibility requirements

Published study evaluates multi-signal fault diagnosis and automated remediation across 186 controlled Kubernetes trials

Company highlights simulation-based findings on autonomous fleet reliability and a later patent application’s citation of Pola’s earlier invention

November and December events include a pickleball tournament, a hosted bar crawl, a Jersey Shore surf contest and a holiday kickoff party

Article explores how citizenship-based obligations can affect tax, estate, mobility, and long-term financial planning for families with ties to Canada and the United States

LOS ANGELES, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Flotek Industries, Inc. (“Flotek” or “the Company”) (NYSE: FTK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® —

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Flotek Industries To Contact Him Directly To Discuss Their Options

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In York To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Innventure To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hyliion To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In XTI Aerospace To Contact Him Directly To Discuss Their Options

Pre-specified and Statistically Powered Key Endpoints Included Progression-free Survival (PFS) and Overall Survival (OS). Although Primary Endpoint of PFS Was Not Met, The Key Secondary Endpoint of OS Was Improved With VAZKEPA/VASCEPA

GERMANTOWN, Md., Oct. 25, 2026 (GLOBE NEWSWIRE) -- AirTripMaker, a growing travel platform focused on connecting travelers with convenient international air travel options, is expanding its USA and Canada to India travel network to serve passengers traveling from the United States or Canada to India’s most important metropolitan, business, technology, cultural and tourism destinations.

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence 

MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy.

Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027

Guarding the Frontline: How Military Veterans and Emerging Super Intelligence Intersect with DFARS Whistleblower & CA.gov AI Public Safety Mandates

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Innventure (INV) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Flotek securities between August 3, 2026 and August 17, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In XTI (XTIA) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hyliion (HYLN) To Contact Him Directly To Discuss Their Options

CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced updated safety and efficacy data for zolucatetide, the first and only direct inhibitor of the β-catenin:TCF interaction, in patients with desmoid tumors. The data were presented today in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.The updated results, based on a June 22, 2026, data cutoff, include data from both the dose escalation and dose optimization portions of the ongoing Phase 1/2 trial and reinforce the strong efficacy and favorable safety and tolerability profile observed with zolucatetide. Among response-evaluable patients who began treatment at a starting dose of ≥450 mg, zolucatetide demonstrated an objective response rate (ORR) of 72.2% (13/18) in a 32-week landmark analysis. A disease control rate (DCR) of 100% was observed across all 46 response-evaluable patients who received a starting dose of ≥450 mg, with no disease progression.Data from a three-arm randomized dose optimization trial supported selection of a 450 mg weekly induction regimen administered for four cycles, followed by 300 mg every two weeks for long-term maintenance. Following productive end-of-Phase 2 discussions, Parabilis has reached alignment with the U.S. Food and Drug Administration (FDA) on the selected dose and regimen, on the use of a placebo-controlled study design, and on progression-free survival (PFS) as the primary endpoint for registrational development. Parabilis plans to initiate the randomized, double-blind PEDESTAL Phase 3 trial (Phase 3 Evaluation of DESmoid Tumor Activity with zoLucatetide) in the first half of 2027, with topline results anticipated in 2029. “Desmoid tumors are chronic and life-altering for patients, often affecting people at a young age, and patients need treatments that can deliver rapid, deep and durable tumor responses with a tolerability profile suited for long-term treatment,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We designed zolucatetide to directly inhibit β-catenin:TCF, a historically undruggable target at the heart of the biology driving these tumors. The depth and consistency of responses we are seeing, together with the favorable safety and tolerability profile observed to date, reinforce our conviction that zolucatetide has the potential to deliver a truly differentiated medicine and meaningfully expand the number of patients who can benefit from treatment. We are very pleased with the clarity of the FDA’s feedback on our registrational development strategy, and with our Phase 3 regimen selected, we are moving with urgency to bring this medicine to patients.”Updated Phase 1/2 Results As of the June 22, 2026, data cutoff, 76 patients with desmoid tumors had been enrolled and treated across all dose levels in the dose escalation and dose optimization portions of the trial. Median age was 37 years (range 19–80), and 69.7% of patients were female. The population included both patients who had previously been treated with and failed gamma-secretase inhibitors (GSIs) and patients naive to GSIs.